Valero Energy Partners (VLP) Announces Quarterly Results

Share on StockTwits

Valero Energy Partners (NYSE:VLP) released its earnings data on Wednesday. The company reported $0.18 EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.44 by $1.26, AnalystRatingsNetwork reports. The company had revenue of $21.53 million for the quarter, compared to the consensus estimate of $22.60 million. The company’s quarterly revenue was down 8.5% on a year-over-year basis.

A number of research firms have recently commented on VLP. Analysts at Barclays raised their price target on shares of Valero Energy Partners from $41.00 to $46.00 in a research note on Thursday. They now have an “overweight” rating on the stock. On the ratings front, analysts at Credit Suisse raised their price target on shares of Valero Energy Partners from $38.00 to $44.00 in a research note on Thursday. Finally, analysts at RBC Capital raised their price target on shares of Valero Energy Partners from $44.00 to $50.00 in a research note on Thursday. They now have an “outperform” rating on the stock. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $44.07.

Shares of Valero Energy Partners (NYSE:VLP) opened at 43.60 on Thursday. Valero Energy Partners has a 52-week low of $27.50 and a 52-week high of $45.16. The stock’s 50-day moving average is $41.51 and its 200-day moving average is $37.11. The company has a market cap of $2.511 billion and a price-to-earnings ratio of 1243.43.

Valero Energy Partners LP was formed to own, operate, develop and acquire crude oil and refined petroleum products pipelines, terminals and other transportation and logistics assets.

Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.

Latest News

Flonase Approved by FDA for OTC Use in U.S.
Flonase Approved by FDA for OTC Use in U.S.
Coca-Cola Announces Disappointing Second Quarter Results
Coca-Cola Announces Disappointing Second Quarter Results
Joint Venture Between Exxon Mobile And Russian Company Reports Progress
Joint Venture Between Exxon Mobile And Russian Company Reports Progress
Profit at Boeing Up with Strong Performance
Profit at Boeing Up with Strong Performance
Layoffs Hit Microsoft Employees Hard
Layoffs Hit Microsoft Employees Hard
New Amazon E-Book Subscription Service Raises Some Eyebrows
New Amazon E-Book Subscription Service Raises Some Eyebrows


Leave a Reply

 
© 2006-2014 Zolmax.